Avelumab in G2-3 NET

Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2017
This is a single-center, single-arm, open-label, phase II trial to evaluate the efficacy and safety of avelumab in subjects with unresectable or metastatic, Grade 2-3, well-differentiated neuroendocrine.tumour.
Epistemonikos ID: 647aa2017f2364aab9a9b3067630123b954baf1d
First added on: May 21, 2024